Search

Your search keyword '"Bertsias, George"' showing total 848 results
Start Over Author "Bertsias, George"
848 results on '"Bertsias, George"'

53. The genomic landscape of ANCA-associated vasculitis: Distinct transcriptional signatures, molecular endotypes and comparison with systemic lupus erythematosus

Author

Banos, Aggelos, primary, Thomas, Konstantinos, additional, Garantziotis, Panagiotis, additional, Filia, Anastasia, additional, Malissovas, Nikolaos, additional, Pieta, Antigone, additional, Nikolakis, Dimitrios, additional, Panagiotopoulos, Alexandros G., additional, Chalkia, Aglaia, additional, Petras, Dimitrios, additional, Bertsias, George, additional, Boumpas, Dimitrios T., additional, and Vassilopoulos, Dimitrios, additional

Published
2023
Full Text
View/download PDF

54. EULAR study group on ‘MHC-I-opathy’: identifying disease-overarching mechanisms across disciplines and borders

Author

Kuiper, Jonas JW, primary, Prinz, Jörg C, additional, Stratikos, Efstratios, additional, Kuśnierczyk, Piotr, additional, Arakawa, Akiko, additional, Springer, Sebastian, additional, Mintoff, Dillon, additional, Padjen, Ivan, additional, Shumnalieva, Russka, additional, Vural, Seçil, additional, Kötter, Ina, additional, van de Sande, Marleen G, additional, Boyvat, Ayşe, additional, de Boer, Joke H, additional, Bertsias, George, additional, de Vries, Niek, additional, Krieckaert, Charlotte LM, additional, Leal, Inês, additional, Vidovič Valentinčič, Nataša, additional, Tugal-Tutkun, Ilknur, additional, el Khaldi Ahanach, Hanane, additional, Costantino, Félicie, additional, Glatigny, Simon, additional, Mrazovac Zimak, Danijela, additional, Lötscher, Fabian, additional, Kerstens, Floor G, additional, Bakula, Marija, additional, Viera Sousa, Elsa, additional, Böhm, Peter, additional, Bosman, Kees, additional, Kenna, Tony J, additional, Powis, Simon J, additional, Breban, Maxime, additional, Gul, Ahmet, additional, Bowes, John, additional, Lories, Rik JU, additional, Nowatzky, Johannes, additional, Wolbink, Gerrit Jan, additional, McGonagle, Dennis G, additional, and Turkstra, Franktien, additional

Published
2023
Full Text
View/download PDF

56. ERN ReCONNET points to consider for treating patients living with autoimmune rheumatic diseases with antiviral therapies and anti-SARS-CoV-2 antibody products

Author

Talarico, Rosaria, primary, Ramirez, Giuseppe Alvise, additional, Barreira, Sofia C., additional, Cardamone, Chiara, additional, Triggianese, Paola, additional, Aguilera, Silvia, additional, Andersen, Jeanette, additional, Avcin, Tadej, additional, Benistan, Karelle, additional, Bertsias, George, additional, Bortoluzzi, Alessandra, additional, Bouillot, Coralie, additional, Bulina, Inita, additional, Burmester, Gerd R., additional, Callens, Steven, additional, Carreira, Patricia E., additional, Cervera, Ricard, additional, Cutolo, Maurizio, additional, Damian, Laura, additional, Della-Torre, Emanuel, additional, Faria, Raquel, additional, Fonseca, João E., additional, Galetti, Ilaria, additional, Hachulla, Eric, additional, Iaccarino, Luca, additional, Jacobsen, Søren, additional, Khmelinskii, Nikita, additional, Limper, Maarten, additional, Marinello, Diana, additional, Meyer, Alain, additional, Moroncini, Gianluca, additional, Nagy, Gyorgy, additional, Olesinska, Marzena, additional, Pamfil, Cristina, additional, Pileckyte, Margarita, additional, Pistello, Mauro, additional, Rednic, Simona, additional, Richez, Christophe, additional, Romão, Vasco C., additional, Schneider, Matthias, additional, Sciascia, Savino, additional, Scirè, Carlo Alberto, additional, Simonini, Gabriele, additional, Smith, Vanessa, additional, Sulli, Alberto, additional, Tani, Chiara, additional, Tas, Sander W., additional, Tincani, Angela, additional, Vonk, Madelon C., additional, Tektonidou, Maria, additional, and Mosca, Marta, additional

Published
2023
Full Text
View/download PDF

57. 2022 EULAR points to consider for the measurement, reporting and application of IFN-I pathway activation assays in clinical research and practice

Author

Rodríguez-Carrio, Javier, primary, Burska, Agata, additional, Conaghan, Philip G, additional, Dik, Willem A, additional, Biesen, Robert, additional, Eloranta, Maija-Leena, additional, Cavalli, Giulio, additional, Visser, Marianne, additional, Boumpas, Dimitrios T, additional, Bertsias, George, additional, Wahren-Herlenius, Marie, additional, Rehwinkel, Jan, additional, Frémond, Marie-Louise, additional, Crow, Mary K, additional, Rönnblom, Lars, additional, Versnel, Marjan A, additional, and Vital, Edward M, additional

Published
2023
Full Text
View/download PDF

58. Type I interferon pathway assays in studies of rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider

Author

Burska, Agata, primary, Rodríguez-Carrio, Javier, additional, Biesen, Robert, additional, Dik, Willem A, additional, Eloranta, Maija-Leena, additional, Cavalli, Giulio, additional, Visser, Marianne, additional, Boumpas, Dimitrios T, additional, Bertsias, George, additional, Wahren-Herlenius, Marie, additional, Rehwinkel, Jan, additional, Frémond, Marie-Louise, additional, Crow, Mary K, additional, Ronnblom, Lars, additional, Conaghan, PG, additional, Versnel, Marjan, additional, and Vital, Ed, additional

Published
2023
Full Text
View/download PDF

59. Association between type I interferon pathway activation and clinical outcomes in rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider

Author

Rodríguez-Carrio, Javier, primary, Burska, Agata, additional, Conaghan, P G, additional, Dik, Willem A, additional, Biesen, Robert, additional, Eloranta, Maija-Leena, additional, Cavalli, Giulio, additional, Visser, Marianne, additional, Boumpas, Dimitrios T, additional, Bertsias, George, additional, Wahren-Herlenius, Marie, additional, Rehwinkel, Jan, additional, Frémond, Marie-Louise, additional, Crow, Mary K, additional, Ronnblom, Lars, additional, Vital, Ed, additional, and Versnel, Marjan, additional

Published
2023
Full Text
View/download PDF

60. 2022 EULAR points to consider for the measurement, reporting and application of IFN-I pathway activation assays in clinical research and practice

Author

Rodriguez-Carrio, Javier, Burska, Agata, Conaghan, Philip G., Dik, Willem A., Biesen, Robert, Eloranta, Maija-Leena, Cavalli, Giulio, Visser, Marianne, Boumpas, Dimitrios T., Bertsias, George, Wahren-Herlenius, Marie, Rehwinkel, Jan, Fremond, Marie-Louise, Crow, Mary K., Rönnblom, Lars, Versnel, Marjan A., Vital, Edward M., Rodriguez-Carrio, Javier, Burska, Agata, Conaghan, Philip G., Dik, Willem A., Biesen, Robert, Eloranta, Maija-Leena, Cavalli, Giulio, Visser, Marianne, Boumpas, Dimitrios T., Bertsias, George, Wahren-Herlenius, Marie, Rehwinkel, Jan, Fremond, Marie-Louise, Crow, Mary K., Rönnblom, Lars, Versnel, Marjan A., and Vital, Edward M.

Abstract

Background: Type I interferons (IFN-Is) play a role in a broad range of rheumatic and musculoskeletal diseases (RMDs), and compelling evidence suggests that their measurement could have clinical value, although testing has not progressed into clinical settings. Objective: To develop evidence-based points to consider (PtC) for the measurement and reporting of IFN-I assays in clinical research and to determine their potential clinical utility. Methods: EULAR standardised operating procedures were followed. A task force including rheumatologists, immunologists, translational scientists and a patient partner was formed. Two systematic reviews were conducted to address methodological and clinical questions. PtC were formulated based on the retrieved evidence and expert opinion. Level of evidence and agreement was determined. Results: Two overarching principles and 11 PtC were defined. The first set (PtC 1-4) concerned terminology, assay characteristics and reporting practices to enable more consistent reporting and facilitate translation and collaborations. The second set (PtC 5-11) addressed clinical applications for diagnosis and outcome assessments, including disease activity, prognosis and prediction of treatment response. The mean level of agreement was generally high, mainly in the first PtC set and for clinical applications in systemic lupus erythematosus. Harmonisation of assay methodology and clinical validation were key points for the research agenda. Conclusions: IFN-I assays have a high potential for implementation in the clinical management of RMDs. Uptake of these PtC will facilitate the progress of IFN-I assays into clinical practice and may be also of interest beyond rheumatology.

Published
2023
Full Text
View/download PDF

61. Type I interferon pathway assays in studies of rheumatic and musculoskeletal diseases : a systematic literature review informing EULAR points to consider

Author

Burska, Agata, Rodriguez-Carrio, Javier, Biesen, Robert, Dik, Willem A., Eloranta, Maija-Leena, Cavalli, Giulio, Visser, Marianne, Boumpas, Dimitrios T., Bertsias, George, Wahren-Herlenius, Marie, Rehwinkel, Jan, Fremond, Marie-Louise, Crow, Mary K., Rönnblom, Lars, Conaghan, P. G., Versnel, Marjan, Vital, Ed, Burska, Agata, Rodriguez-Carrio, Javier, Biesen, Robert, Dik, Willem A., Eloranta, Maija-Leena, Cavalli, Giulio, Visser, Marianne, Boumpas, Dimitrios T., Bertsias, George, Wahren-Herlenius, Marie, Rehwinkel, Jan, Fremond, Marie-Louise, Crow, Mary K., Rönnblom, Lars, Conaghan, P. G., Versnel, Marjan, and Vital, Ed

Abstract

ObjectivesTo systematically review the literature for assay methods that aim to evaluate type I interferon (IFN-I) pathway activation and to harmonise-related terminology.MethodsThree databases were searched for reports of IFN-I and rheumatic musculoskeletal diseases. Information about the performance metrics of assays measuring IFN-I and measures of truth were extracted and summarised. A EULAR task force panel assessed feasibility and developed consensus terminology.ResultsOf 10 037 abstracts, 276 fulfilled eligibility criteria for data extraction. Some reported more than one technique to measure IFN-I pathway activation. Hence, 276 papers generated data on 412 methods. IFN-I pathway activation was measured using: qPCR (n=121), immunoassays (n=101), microarray (n=69), reporter cell assay (n=38), DNA methylation (n=14), flow cytometry (n=14), cytopathic effect assay (n=11), RNA sequencing (n=9), plaque reduction assay (n=8), Nanostring (n=5), bisulphite sequencing (n=3). Principles of each assay are summarised for content validity. Concurrent validity (correlation with other IFN assays) was presented for n=150/412 assays. Reliability data were variable and provided for 13 assays. Gene expression and immunoassays were considered most feasible. Consensus terminology to define different aspects of IFN-I research and practice was produced.ConclusionsDiverse methods have been reported as IFN-I assays and these differ in what elements or aspects of IFN-I pathway activation they measure and how. No 'gold standard' represents the entirety of the IFN pathway, some may not be specific for IFN-I. Data on reliability or comparing assays were limited, and feasibility is a challenge for many assays. Consensus terminology should improve consistency of reporting.

Published
2023
Full Text
View/download PDF

62. Association between type I interferon pathway activation and clinical outcomes in rheumatic and musculoskeletal diseases : a systematic literature review informing EULAR points to consider

Author

Rodriguez-Carrio, Javier, Burska, Agata, Conaghan, P. G., Dik, Willem A., Biesen, Robert, Eloranta, Maija-Leena, Cavalli, Giulio, Visser, Marianne, Boumpas, Dimitrios T., Bertsias, George, Wahren-Herlenius, Marie, Rehwinkel, Jan, Fremond, Marie-Louise, Crow, Mary K., Rönnblom, Lars, Vital, Ed, Versnel, Marjan, Rodriguez-Carrio, Javier, Burska, Agata, Conaghan, P. G., Dik, Willem A., Biesen, Robert, Eloranta, Maija-Leena, Cavalli, Giulio, Visser, Marianne, Boumpas, Dimitrios T., Bertsias, George, Wahren-Herlenius, Marie, Rehwinkel, Jan, Fremond, Marie-Louise, Crow, Mary K., Rönnblom, Lars, Vital, Ed, and Versnel, Marjan

Abstract

BackgroundType I interferons (IFN-I) contribute to a broad range of rheumatic and musculoskeletal diseases (RMDs). Compelling evidence suggests that the measurement of IFN-I pathway activation may have clinical value. Although several IFN-I pathway assays have been proposed, the exact clinical applications are unclear. We summarise the evidence on the potential clinical utility of assays measuring IFN-I pathway activation.MethodsA systematic literature review was conducted across three databases to evaluate the use of IFN-I assays in diagnosis and monitor disease activity, prognosis, response to treatment and responsiveness to change in several RMDs.ResultsOf 366 screened, 276 studies were selected that reported the use of assays reflecting IFN-I pathway activation for disease diagnosis (n=188), assessment of disease activity (n=122), prognosis (n=20), response to treatment (n=23) and assay responsiveness (n=59). Immunoassays, quantitative PCR (qPCR) and microarrays were reported most frequently, while systemic lupus erythematosus (SLE), rheumatoid arthritis, myositis, systemic sclerosis and primary Sjogren's syndrome were the most studied RMDs. The literature demonstrated significant heterogeneity in techniques, analytical conditions, risk of bias and application in diseases. Inadequate study designs and technical heterogeneity were the main limitations. IFN-I pathway activation was associated with disease activity and flare occurrence in SLE, but their incremental value was uncertain. IFN-I pathway activation may predict response to IFN-I targeting therapies and may predict response to different treatments.ConclusionsEvidence indicates potential clinical value of assays measuring IFN-I pathway activation in several RMDs, but assay harmonisation and clinical validation are urged. This review informs the EULAR points to consider for the measurement and reporting of IFN-I pathway assays.

Published
2023
Full Text
View/download PDF

63. Association between type I interferon pathway activation and clinical outcomes in rheumatic and musculoskeletal diseases:a systematic literature review informing EULAR points to consider

Author

Rodríguez-Carrio, Javier, Burska, Agata, Conaghan, P. G., Dik, Willem A., Biesen, Robert, Eloranta, Maija Leena, Cavalli, Giulio, Visser, Marianne, Boumpas, Dimitrios T., Bertsias, George, Wahren-Herlenius, Marie, Rehwinkel, Jan, Frémond, Marie Louise, Crow, Mary K., Ronnblom, Lars, Vital, Ed, Versnel, Marjan, Rodríguez-Carrio, Javier, Burska, Agata, Conaghan, P. G., Dik, Willem A., Biesen, Robert, Eloranta, Maija Leena, Cavalli, Giulio, Visser, Marianne, Boumpas, Dimitrios T., Bertsias, George, Wahren-Herlenius, Marie, Rehwinkel, Jan, Frémond, Marie Louise, Crow, Mary K., Ronnblom, Lars, Vital, Ed, and Versnel, Marjan

Abstract

Background Type I interferons (IFN-I) contribute to a broad range of rheumatic and musculoskeletal diseases (RMDs). Compelling evidence suggests that the measurement of IFN-I pathway activation may have clinical value. Although several IFN-I pathway assays have been proposed, the exact clinical applications are unclear. We summarise the evidence on the potential clinical utility of assays measuring IFN-I pathway activation. Methods A systematic literature review was conducted across three databases to evaluate the use of IFN-I assays in diagnosis and monitor disease activity, prognosis, response to treatment and responsiveness to change in several RMDs. Results Of 366 screened, 276 studies were selected that reported the use of assays reflecting IFN-I pathway activation for disease diagnosis (n=188), assessment of disease activity (n=122), prognosis (n=20), response to treatment (n=23) and assay responsiveness (n=59). Immunoassays, quantitative PCR (qPCR) and microarrays were reported most frequently, while systemic lupus erythematosus (SLE), rheumatoid arthritis, myositis, systemic sclerosis and primary Sjögren's syndrome were the most studied RMDs. The literature demonstrated significant heterogeneity in techniques, analytical conditions, risk of bias and application in diseases. Inadequate study designs and technical heterogeneity were the main limitations. IFN-I pathway activation was associated with disease activity and flare occurrence in SLE, but their incremental value was uncertain. IFN-I pathway activation may predict response to IFN-I targeting therapies and may predict response to different treatments. Conclusions Evidence indicates potential clinical value of assays measuring IFN-I pathway activation in several RMDs, but assay harmonisation and clinical validation are urged. This review informs the EULAR points to consider for the measurement and reporting of IFN-I pathway assays.

Published
2023

64. Type I interferon pathway assays in studies of rheumatic and musculoskeletal diseases:a systematic literature review informing EULAR points to consider

Author

Burska, Agata, Rodríguez-Carrio, Javier, Biesen, Robert, Dik, Willem A., Eloranta, Maija Leena, Cavalli, Giulio, Visser, Marianne, Boumpas, Dimitrios T., Bertsias, George, Wahren-Herlenius, Marie, Rehwinkel, Jan, Frémond, Marie Louise, Crow, Mary K., Ronnblom, Lars, Conaghan, P. G., Versnel, Marjan, Vital, Ed, Burska, Agata, Rodríguez-Carrio, Javier, Biesen, Robert, Dik, Willem A., Eloranta, Maija Leena, Cavalli, Giulio, Visser, Marianne, Boumpas, Dimitrios T., Bertsias, George, Wahren-Herlenius, Marie, Rehwinkel, Jan, Frémond, Marie Louise, Crow, Mary K., Ronnblom, Lars, Conaghan, P. G., Versnel, Marjan, and Vital, Ed

Abstract

Objectives To systematically review the literature for assay methods that aim to evaluate type I interferon (IFN-I) pathway activation and to harmonise-related terminology. Methods Three databases were searched for reports of IFN-I and rheumatic musculoskeletal diseases. Information about the performance metrics of assays measuring IFN-I and measures of truth were extracted and summarised. A EULAR task force panel assessed feasibility and developed consensus terminology. Results Of 10 037 abstracts, 276 fulfilled eligibility criteria for data extraction. Some reported more than one technique to measure IFN-I pathway activation. Hence, 276 papers generated data on 412 methods. IFN-I pathway activation was measured using: qPCR (n=121), immunoassays (n=101), microarray (n=69), reporter cell assay (n=38), DNA methylation (n=14), flow cytometry (n=14), cytopathic effect assay (n=11), RNA sequencing (n=9), plaque reduction assay (n=8), Nanostring (n=5), bisulphite sequencing (n=3). Principles of each assay are summarised for content validity. Concurrent validity (correlation with other IFN assays) was presented for n=150/412 assays. Reliability data were variable and provided for 13 assays. Gene expression and immunoassays were considered most feasible. Consensus terminology to define different aspects of IFN-I research and practice was produced. Conclusions Diverse methods have been reported as IFN-I assays and these differ in what elements or aspects of IFN-I pathway activation they measure and how. No â € gold standard' represents the entirety of the IFN pathway, some may not be specific for IFN-I. Data on reliability or comparing assays were limited, and feasibility is a challenge for many assays. Consensus terminology should improve consistency of reporting.

Published
2023

65. Global comment on the use of hydroxychloroquine during the periconception period and pregnancy in women with autoimmune diseases

Author

Schreiber, Karen, Giles, Ian, Costedoat-Chalumeau, Nathalie, Nelson-Piercy, Catherine, Dolhain, Radboud Jem, Mosca, Marta, Förger, Frauke, Fischer-Betz, Rebecca, Molto, Anna, Tincani, Angela, Pasquier, Elisabeth, Marin, Benoit, Elefant, Elisabeth, Salmon, Jane, Bermas, Bonnie L, Sammaritano, Lisa, Clowse, Megan E B, Chambers, Christina, Buyon, Jill, Inoue, Saori Abe, Agmon-Levin, Nancy, Aguilera, Silvia, Emadi, Samar Al, Andersen, Jeanette, Andrade, Danieli, Antovic, Aleksandra, Arnaud, Laurent, Christiansen, Alice Ashouri, Avcin, Tadej, Badreh-Wirström, Sara, Bertsias, George, Bini, Ilaria, Bobirca, Anca, Branch, Ware, Brucato, Antonio, Bultink, Irene, Capela, Susanna, Cecchi, Irene, Cervera, Ricard, Chighizola, Cecilia, Cobilinschi, Claudia, Cuadrado, Maria Jose, Dey, Dzifa, Etomi, Oseme, Espinosa, Gerard, Flint, Julia, Fonseca, João-Eurico, Fritsch-Stork, Ruth, Gerosa, Maria, Glintborg, Bente, Skorpen, Carina Gøtestam, Goulden, Bethan, Graversgaard, Christine, Gunnarsson, Iva, Gupta, Latika, Hetland, Merete, Hodson, Ken, Hunt, Beverley J, Isenberg, David, Jacobsen, Søren, Khamashta, Munther, Levy, Roger, Linde, Louise, Lykke, Jacob, Meissner, Yvette, Moore, Louise, Morand, Eric, Navarra, Sandra, Opris-Belinski, Daniela, Østensen, Monika, Ozawa, Hiroki, Perez-Garcia, Luis Fernando, Petri, Michelle, Pons-Estel, Guillermo J, Radin, Massimo, Raio, Luigi, Rottenstreich, Amihai, Ruiz-Irastorza, Guillermo, Tunjić, Slađana Rumpl, Rygg, Marite, Sciascia, Savino, Strangfeld, Anja, Svenungsson, Elisabet, Tektonidou, Maria, Troldborg, Anne, Vinet, Evelyne, Vojinovic, Jelena, Voss, Anne, Wallenius, Marianne, Andreoli, Laura, Schreiber, Karen, Giles, Ian, Costedoat-Chalumeau, Nathalie, Nelson-Piercy, Catherine, Dolhain, Radboud Jem, Mosca, Marta, Förger, Frauke, Fischer-Betz, Rebecca, Molto, Anna, Tincani, Angela, Pasquier, Elisabeth, Marin, Benoit, Elefant, Elisabeth, Salmon, Jane, Bermas, Bonnie L, Sammaritano, Lisa, Clowse, Megan E B, Chambers, Christina, Buyon, Jill, Inoue, Saori Abe, Agmon-Levin, Nancy, Aguilera, Silvia, Emadi, Samar Al, Andersen, Jeanette, Andrade, Danieli, Antovic, Aleksandra, Arnaud, Laurent, Christiansen, Alice Ashouri, Avcin, Tadej, Badreh-Wirström, Sara, Bertsias, George, Bini, Ilaria, Bobirca, Anca, Branch, Ware, Brucato, Antonio, Bultink, Irene, Capela, Susanna, Cecchi, Irene, Cervera, Ricard, Chighizola, Cecilia, Cobilinschi, Claudia, Cuadrado, Maria Jose, Dey, Dzifa, Etomi, Oseme, Espinosa, Gerard, Flint, Julia, Fonseca, João-Eurico, Fritsch-Stork, Ruth, Gerosa, Maria, Glintborg, Bente, Skorpen, Carina Gøtestam, Goulden, Bethan, Graversgaard, Christine, Gunnarsson, Iva, Gupta, Latika, Hetland, Merete, Hodson, Ken, Hunt, Beverley J, Isenberg, David, Jacobsen, Søren, Khamashta, Munther, Levy, Roger, Linde, Louise, Lykke, Jacob, Meissner, Yvette, Moore, Louise, Morand, Eric, Navarra, Sandra, Opris-Belinski, Daniela, Østensen, Monika, Ozawa, Hiroki, Perez-Garcia, Luis Fernando, Petri, Michelle, Pons-Estel, Guillermo J, Radin, Massimo, Raio, Luigi, Rottenstreich, Amihai, Ruiz-Irastorza, Guillermo, Tunjić, Slađana Rumpl, Rygg, Marite, Sciascia, Savino, Strangfeld, Anja, Svenungsson, Elisabet, Tektonidou, Maria, Troldborg, Anne, Vinet, Evelyne, Vojinovic, Jelena, Voss, Anne, Wallenius, Marianne, and Andreoli, Laura

Published
2023

67. Erythrodermic psoriasis after rituximab treatment in a patient with autoimmune hemolytic anemia

Author

Koumaki, Dimitra, Koumaki, Vasiliki, Haniotis, Vrettos, Katoulis, Alexander, Boumpoucheropoulos, Sotirios, Stefanidou, Maria, Pontikoglou, Charalampos, Bertsias, George, Evangelou, George, Zografaki, Kyriaki, Mantaka, Aikaterini, Krueger-Krasagakis, Sabine, and Krasagakis, Konstantinos

Subjects
Psoriasis -- Drug therapy, Insulin glargine, Antineoplastic agents, Type 2 diabetes -- Drug therapy, Hemolytic anemia -- Drug therapy, Antimitotic agents, Health
Abstract

Byline: Dimitra. Koumaki, Vasiliki. Koumaki, Vrettos. Haniotis, Alexander. Katoulis, Sotirios. Boumpoucheropoulos, Maria. Stefanidou, Charalampos. Pontikoglou, George. Bertsias, George. Evangelou, Kyriaki. Zografaki, Aikaterini. Mantaka, Sabine. Krueger-Krasagakis, Konstantinos. Krasagakis Sir, A 57-year-old [...]

Published
2021

68. Metabolic syndrome in children and adolescents in Crete, Greece, and association with diet quality and physical fitness

Author

Linardakis, Manolis, Bertsias, George, Sarri, Katerina, Papadaki, Angeliki, and Kafatos, Anthony

Abstract

Abstract: Aim: To determine the prevalence of metabolic syndrome in children and adolescents in Crete (Greece) and examine associations with diet quality and physical fitness. Subjects and Methods: A representative sample of 1,209 Cretan children and adolescents aged 3–17 1/2 years participated in this cross-sectional survey. The study took place in kindergartens, primary and secondary schools in the cities of Heraklion and Chania and kindergartens and schools in semi-urban and rural regions outside Heraklion. The metabolic syndrome was defined as the presence of ≥3 of: impaired fasting blood glucose, hypertension, abdominal obesity, hypertriglyceridaemia, and low HDL-cholesterol. Diet quality was assessed by the Healthy Eating Index score (USDA) and physical fitness by the 20-m shuttle run test. Results: Approximately 4% of Cretan children and adolescents assessed (4.2% of boys, 3.6% of girls) had three or more metabolic syndrome factors. Over 25% of the subjects had a “poor” diet, defined as Healthy Eating Index <51, and higher diet quality scores correlated with decreased mean body mass index, waist/height ratio, systolic blood pressure, total cholesterol, and number of metabolic syndrome risk factors present. Clustering of metabolic syndrome risk factors was also associated with decreased physical fitness, as well as increased body mass index, waist/height ratio and total cholesterol/HDL-cholesterol ratio. Conclusions: Presence of three or more factors related to the metabolic syndrome was strongly associated with poor diet quality and low physical fitness, as well as overweight, in Cretan children and adolescents. Health promotion strategies in childhood should encourage weight control, the establishment of healthier dietary patterns, and adequate physical activity, as a means of preventing the increase in the prevalence of this public health issue.

Published
2024
Full Text
View/download PDF

69. Multidisciplinary approach to lupus nephritis: Clinical pearls, pitfalls, and positioning of newly-approved agents.

Author

Fanouriakis, Antonis, Bertsias, George, Liapis, George, Marinaki, Smaragdi, Papagianni, Aikaterini, Stangou, Maria, Garyfallos, Alexandros, Lionaki, Sophia, Tektonidou, Maria G., Boletis, John N., and Boumpas, Dimitrios T

Subjects
*LUPUS nephritis, *SYSTEMIC lupus erythematosus, *RENAL biopsy, *NEPHROTIC syndrome, *MYCOPHENOLIC acid, *PROTEINURIA
Abstract

Lupus nephritis (LN) is a major course of morbidity and mortality in patients with systemic lupus erythematosus (SLE), best managed by a multidisciplinary group. To this end, we gathered a group of rheumatologists, nephrologists and a nephropathologist to review current evidence regarding diagnosis and management of LN. In this consensus paper, we summarize the key points from this meeting and provide practice guidelines for the management of kidney involvement in SLE, in view of emerging new data concerning novel agents approved recently. Renal biopsy is indispensable for the management of LN. Yet, important pearls and pitfalls need to be considered regarding indications and interpretation, which are summarized in informative tables. In new-onset LN, experts agreed that, although belimumab may be added from disease onset, patients with moderate to severe proliferative nephritis (defined as: NIH activity index > 5 plus ≥ 1 of the following: (i) NIH chronicity index > 2, (ii) proteinuria > 3 g /24 h, and (iii) increase in serum creatinine > 20%) may be more likely to benefit the most. In all other patients who have already started standard-of-care treatment with either mycophenolate mofetil (MMF) or cyclophosphamide (CY), belimumab could be considered in cases with an inadequate clinical response by 3 months, or in cases that experience a nephritic flare following initial response, or have an inability to reduce the dose of glucocorticoids. In all circumstances, the drug should be given as add-on therapy, that is, in combination with a standard-of-care therapy (MMF or CY). Voclosporin could be considered for up to 3 years, in combination with MMF, in patients with heavy proteinuria (well above the nephrotic range), wherein a quick reduction of protein loss in urine is desirable to avoid the complications of the nephrotic syndrome, either as part of the initial regimen, or in cases of inadequate reduction of proteinuria with MMF. In view of the potential scarring effects, long-term administration beyond the first year requires further documentation. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

70. Clinical response trajectories and drug persistence in systemic lupus erythematosus patients on belimumab treatment: A real-life, multicentre observational study

Author

Nikoloudaki, Myrto, primary, Nikolopoulos, Dionysis, additional, Koutsoviti, Sofia, additional, Flouri, Irini, additional, Kapsala, Noemin, additional, Repa, Argyro, additional, Katsimbri, Pelagia, additional, Theotikos, Evangelos, additional, Pitsigavdaki, Sofia, additional, Pateromichelaki, Katerina, additional, Bertsias, Antonios, additional, Elezoglou, Antonia, additional, Sidiropoulos, Prodromos, additional, Fanouriakis, Antonis, additional, Boumpas, Dimitrios, additional, and Bertsias, George, additional

Published
2023
Full Text
View/download PDF

71. Correction: Nikoloudaki et al. Persistence of Depression and Anxiety despite Short-Term Disease Activity Improvement in Patients with Systemic Lupus Erythematosus: A Single-Centre, Prospective Study. J. Clin. Med. 2022, 11, 4316

Author

Nikoloudaki, Myrto, primary, Repa, Argyro, additional, Pitsigavdaki, Sofia, additional, Sali, Ainour Molla Ismail, additional, Sidiropoulos, Prodromos, additional, Lionis, Christos, additional, and Bertsias, George, additional

Published
2022
Full Text
View/download PDF

72. Investigation of Neutrophil Extracellular Trap (NET) Induction in Patients with Chronic Idiopathic Neutropenia Bearing Mutations in the Mediterranean Fever (MEFV) Gene

Author

Karkempetzaki, Iris, primary, Mavroudi, Irene, additional, Tsaknakis, Grigorios, additional, Nikoleri, Dimitra, additional, Georgakis, Spiros, additional, Bertsias, George, additional, Goulielmos, George, additional, Chrysanthopoulou, Akrivi, additional, Skendros, Panagiotis, additional, Ritis, Konstantinos, additional, and Papadaki, Helen A., additional

Published
2022
Full Text
View/download PDF

73. IL-6 Signaling Attenuates TNF-α Production by Plasmacytoid Dendritic Cells in Rheumatoid Arthritis

Author

Papadaki, Garyfalia, primary, Goutakoli, Panagiota, additional, Tiniakou, Ioanna, additional, Grün, Joachim R., additional, Grützkau, Andreas, additional, Pavlopoulos, Georgios A., additional, Iliopoulos, Ioannis, additional, Bertsias, George, additional, Boumpas, Dimitrios, additional, Ospelt, Caroline, additional, Reizis, Boris, additional, Sidiropoulos, Prodromos, additional, and Verginis, Panayotis, additional

Published
2022
Full Text
View/download PDF

77. Contributors

Author

Abramson, Steven, primary, An, KaiNan, additional, Andrade, Felipe, additional, Ardoin, Stacy P., additional, Barton, Anne, additional, Baughman, Robert P., additional, Beaton, Dorcas E., additional, Beere, Helen M., additional, Beltran, Javier, additional, Bending, David, additional, Bennett, Robert M., additional, Bermas, Bonnie L., additional, Bertsias, George, additional, Bhardwaj, Nina, additional, Bijlsma, Johannes W.J., additional, Bockenstedt, Linda K., additional, Boers, Maarten, additional, Boilard, Eric, additional, Boin, Francesco, additional, Boumpas, Dimitrios T., additional, Boyle, David L., additional, Bradley, Sean, additional, Brown, Matthew, additional, Buch, Maya, additional, Buckley, Christopher D., additional, Budd, Ralph C., additional, Burg, Nathalie, additional, Burns, Christopher M., additional, Cannella, Amy C., additional, Carter, John D., additional, Chakravarty, Eliza F., additional, Chakravarty, Soumya D., additional, Chang, Christopher, additional, Cheng, Joseph S., additional, Chiodo, Christopher P., additional, Chung, Sharon, additional, Cleland, Leslie G., additional, Cohen, Stanley, additional, Colbert, Robert A., additional, Cook, Paul P., additional, Craft, Joseph E., additional, Crofford, Leslie J., additional, Cronstein, Bruce N., additional, Crow, Mary K., additional, Crowson, Cynthia S., additional, Culley, Kirsty L., additional, Cunnane, Gaye, additional, Dall'Era, Maria, additional, Darrah, Erika, additional, Davis, John M., additional, Bari, Cosimo De, additional, Dell'Accio, Francesco, additional, Diamond, Betty, additional, Di Cesare, Paul E., additional, Dixit, Rajiv, additional, Drenth, Joost P.H., additional, Dustin, Michael L., additional, El-Gabalawy, Hani S., additional, Elmamoun, Musaab, additional, Erickson, Alan R., additional, Erkan, Doruk, additional, Eyre, Stephen, additional, Fanouriakis, Antonis, additional, Felson, David T., additional, Field, Max, additional, Filer, Andrew, additional, Firestein, Gary S., additional, Fishman, Felicity G., additional, FitzGerald, Oliver, additional, Flaherty, John P., additional, Fors, César E., additional, Fortner, Karen A., additional, Gabriel, Sherine E., additional, Gasque, Philippe, additional, Gershwin, M. Eric, additional, Gladue, Heather S., additional, Goldring, Mary B., additional, Goldring, Steven R., additional, Golightly, Yvonne M., additional, Goodman, Stuart, additional, Gordon, Siamon, additional, Grassi, Walter, additional, Green, Douglas R., additional, Greenspan, Adam, additional, Gregersen, Peter, additional, Grimaldi, Christine, additional, Guilherme, Luiza, additional, Hajj-Ali, Rula A., additional, Haudenschild, Dominik R., additional, Hellmann, David B., additional, Holmdahl, Rikard, additional, Hsu, Joyce J., additional, Huddleston, James I., additional, Hudson, Alan P., additional, Huizinga, Thomas W.J., additional, Hunder, Gene G., additional, Iversen, Maura D., additional, Jacobs, Johannes W.G., additional, Jen, Ho, additional, Jordan, Joanne M., additional, Jorizzo, Joseph L., additional, Kalil, Jorge, additional, Kaufman, Kenton, additional, Kaufman, William S., additional, Kavanaugh, Arthur, additional, Keenan, Robert T., additional, Kenna, Tony, additional, Kerr, Darcy A., additional, Koch, Alisa E., additional, Kono, Dwight H., additional, Korsten, Peter, additional, Krakow, Deborah, additional, Krasnokutsky, Svetlana, additional, Lafeber, Floris P.J.G., additional, Lambert, Robert G.W., additional, Lane, Nancy E., additional, Langford, Carol A., additional, Laskin, Daniel M., additional, Layh-Schmitt, Gerlinde, additional, Lee, Lela A., additional, Lee, Tzielan C., additional, Lockshin, Michael D., additional, Lozada, Carlos J., additional, Lundberg, Ingrid E., additional, Luqmani, Raashid, additional, Luyten, Frank P., additional, Mader, Reuven, additional, Maksymowych, Walter, additional, Markenson, Joseph A., additional, Martin, Scott David, additional, Matteson, Eric L., additional, McGregor, Laura, additional, McInnes, Iain B., additional, McNamara, Elizabeth K., additional, Mikuls, Ted R., additional, Miller, Mark S., additional, Ming, Pedro Azevedo, additional, Moder, Kevin G., additional, Monach, Paul A., additional, Moulton, Vaishali R., additional, Nagaraju, Kanneboyina, additional, Nelson, Amanda E., additional, Nigrovic, Peter A., additional, Nistala, Kiran, additional, O'Dell, James R., additional, Okada, Yasunori, additional, Østergaard, Mikkel, additional, Otero, Miguel, additional, Palmer, Bradley M., additional, Panush, Richard S., additional, Peng, Stanford L., additional, Pillai, Shiv, additional, Pillinger, Michael H., additional, Plüddemann, Annette, additional, Polston, Gregory R., additional, Porcelli, Steven A., additional, Price, Mark D., additional, Reed, Ann M., additional, Reveille, John D., additional, Robinson, Angela B., additional, Robinson, Philip, additional, Robinson, William H., additional, Roosendaal, Goris, additional, Rosen, Antony, additional, Rosenbaum, James T., additional, Rosenberg, Andrew E., additional, Ruderman, Eric M., additional, Saag, Kenneth G., additional, Salmon, Jane E., additional, Sammaritano, Lisa R., additional, Samuels, Jonathan, additional, Sandborg, Christy I., additional, Sawalha, Amr H., additional, Saxena, Amit, additional, Schett, Georg, additional, Schutgens, Roger E.G., additional, Seldin, David C., additional, Shah, Binita, additional, Sikora, Keith A., additional, Simon, Anna, additional, Siraj, Dawd S., additional, Sorkin, Linda S., additional, St. Clair, E. William, additional, Stamp, Lisa K., additional, Stone, John H., additional, Suarez-Fueyo, Abel, additional, Svensson, Camilla I., additional, Sweiss, Nadera J., additional, Swigart, Carrie R., additional, Szekanecz, Zoltán, additional, Tait, Stephen, additional, Tanne, Antoine, additional, Taylor, Peter C., additional, Terkeltaub, Robert, additional, Theofilopoulos, Argyrios N., additional, Thornhill, Thomas S., additional, Torok, Kathryn S., additional, Toth, Michael J., additional, Tozman, Elaine C., additional, Trouw, Leendert A., additional, Tsokos, George C., additional, Tugwell, Peter, additional, Tutuncu, Zuhre, additional, Upadhyaya, Shivam, additional, Van, Annette H.M., additional, van der Linden, Sjef, additional, Van, Jos W.M., additional, Van, Jacob M., additional, Meter, Heather Van, additional, van Vollenhoven, Ronald F., additional, van Vulpen, Lize F.D., additional, Varga, John, additional, Vaseer, Samera, additional, Vasquez-Castellanos, Raul, additional, Veale, Douglas J., additional, Wakefield, Richard J., additional, Wallace, Mark S., additional, Wang, Ruoning, additional, Wang, Tingting, additional, Warshaw, David M., additional, Wedderburn, Lucy R., additional, Werth, Victoria P., additional, Wigley, Fredrick M., additional, Wofsy, David, additional, Wollheim, Frank A., additional, Wondimu, Elisabeth, additional, Wong, Cyrus, additional, Wortmann, Robert L., additional, Yelin, Edward, additional, Zayat, Ahmed, additional, Zou, Yong-Rui, additional, and Zurier, Robert B., additional

Published
2017
Full Text
View/download PDF

81. Gender equity in academic rheumatology, current status and potential for improvement: a cross-sectional study to inform an EULAR task force

Author

Ovseiko, Pavel V, primary, Gossec, Laure, additional, Andreoli, Laura, additional, Kiltz, Uta, additional, van Mens, Leonieke, additional, Hassan, Neelam, additional, van der Leeden, Marike, additional, Siddle, Heidi J, additional, Alunno, Alessia, additional, McInnes, Iain B, additional, Damjanov, Nemanja S, additional, Apparailly, Florence, additional, Ospelt, Caroline, additional, van der Horst-Bruinsma, Irene E, additional, Nikiphorou, Elena, additional, Druce, Katie L, additional, Szekanecz, Zoltán, additional, Sepriano, Alexandre, additional, Avcin, Tadej, additional, Bertsias, George, additional, Schett, Georg, additional, Keenan, Anne-Maree, additional, Pololi, Linda H, additional, and Coates, Laura C, additional

Published
2022
Full Text
View/download PDF

82. Cross-species transcriptome analysis for early detection and specific therapeutic targeting of human lupus nephritis

Author

Frangou, Eleni, primary, Garantziotis, Panagiotis, additional, Grigoriou, Maria, additional, Banos, Aggelos, additional, Nikolopoulos, Dionysis, additional, Pieta, Antigone, additional, Doumas, Stavros A, additional, Fanouriakis, Antonis, additional, Hatzioannou, Aikaterini, additional, Manolakou, Theodora, additional, Alissafi, Themis, additional, Verginis, Panayotis, additional, Athanasiadis, Emmanouil, additional, Dermitzakis, Emmanouil, additional, Bertsias, George, additional, Filia, Anastasia, additional, and Boumpas, Dimitrios T, additional

Published
2022
Full Text
View/download PDF

84. Physician Global Assessment International Standardisation COnsensus in Systemic Lupus Erythematosus: the PISCOS study

Author

Piga, Matteo, primary, Chessa, Elisabetta, additional, Morand, Eric F, additional, Ugarte-Gil, Manuel F, additional, Tektonidou, Maria, additional, van Vollenhoven, Ronald, additional, Petri, Michelle, additional, Arnaud, Laurent, additional, Appenzeller, Simone, additional, Aranow, Cynthia, additional, Askanase, Anca, additional, Avcin, Tadej, additional, Bae, Sang-Cheol, additional, Bertsias, George, additional, Bonfa, Eloisa, additional, Cairoli, Ernesto, additional, Cardiel, Mario H, additional, Cervera, Ricard, additional, Chasset, François, additional, Chizzolini, Carlo, additional, Clarke, Ann E, additional, Conti, Fabrizio, additional, Costedoat-Chalumeau, Nathalie, additional, Czirják, László, additional, Doria, Andrea, additional, Dörner, Thomas, additional, Espinosa, Gerard, additional, Fischer-Betz, Rebecca, additional, Garcìa, Mercedes, additional, Gladman, Dafna D, additional, González, Luis A, additional, Gunnarsson, Iva, additional, Hamijoyo, Laniyati, additional, Hanly, John G, additional, Hasni, Sarfaraz A, additional, Houssiau, Frédéric A, additional, Inanç, Murat, additional, Inês, Luís S, additional, Isenberg, David, additional, Jacobsen, Soren, additional, Jan Wu, Yeong-Jian, additional, Kaneko, Yuko, additional, Katsumata, Yasuhiro, additional, Lau, Chak S, additional, Legge, Alexandra C, additional, Lerang, Karoline, additional, Limper, Maarten, additional, Louthrenoo, Worawit, additional, Luo, Shue-Fen, additional, Marinho, António, additional, Massardo, Loreto, additional, Mathian, Alexis, additional, Mosca, Marta, additional, Nikpour, Mandana, additional, Pego-Reigosa, José M, additional, Peschken, Christine A, additional, Pons-Estel, Bernardo A, additional, Pons-Estel, Guillermo J, additional, Rahman, Anisur, additional, Rednic, Simona, additional, Ribi, Camillo, additional, Ruiz-Irastorza, Guillermo, additional, Sato, Emilia I, additional, Saxena, Amit, additional, Schneider, Matthias, additional, Sebastiani, Gian Domenico, additional, Strand, Vibeke, additional, Svenungsson, Elisabet, additional, Tanaka, Yoshiya, additional, Tazi Mezalek, Zoubida, additional, Tee, Michael L, additional, Tincani, Angela, additional, Touma, Zahi, additional, Troldborg, Anne, additional, Vasconcelos, Carlos, additional, Vinet, Évelyne, additional, Vital, Edward M, additional, Voskuyl, Alexandre E, additional, Voss, Anne, additional, Wallace, Daniel, additional, Ward, Michael, additional, and Zamora, Leonid D, additional

Published
2022
Full Text
View/download PDF

86. Molecular Taxonomy of Systemic Lupus Erythematosus Through Data-Driven Patient Stratification

Author

Garantziotis, Panagiotis, Nikolakis, Dimitrios, Doumas, Stavros, Frangou, Eleni, Sentis, George, Filia, Anastasia, Fanouriakis, Antonis, Bertsias, George, Boumpas, Dimitrios T., Graduate School, Clinical Immunology and Rheumatology, and AGEM - Amsterdam Gastroenterology Endocrinology Metabolism

Subjects
B-Lymphocytes, drug response prediction, drug repurposing, systemic lupus erythematosus, endotypes, Immunology, Cluster Analysis, Humans, Lupus Erythematosus, Systemic, Immunology and Allergy, molecular taxonomy, Lupus Nephritis, Severity of Illness Index
Abstract

ObjectivesTreatment of Systemic Lupus Erythematosus (SLE) is characterized by a largely empirical approach and relative paucity of novel compound development. We sought to stratify SLE patients based on their molecular phenotype and identify putative therapeutic compounds for each molecular fingerprint.MethodsBy the use of whole blood RNA-seq data from 120 SLE patients, and in a data-driven, clinically unbiased manner, we established modules of commonly regulated genes (molecular endotypes) and re-stratified patients through hierarchical clustering. Disease activity and severity were assessed using SLEDAI-2K and Lupus Severity Index, respectively. Through an in silico drug prediction pipeline, we investigated drugs currently in use, tested in lupus clinical trials, and listed in the iLINCS prediction databases, for their ability to reverse the gene expression signatures in each molecular endotype. Drug repurposing analysis was also performed to identify perturbagens that counteract group-specific SLE signatures.ResultsMolecular taxonomy identified five lupus endotypes, each characterized by a unique gene module enrichment pattern. Neutrophilic signature group consisted primarily of patients with active lupus nephritis, while the B-cell expression group included patients with constitutional features. Patients with moderate severity and serologic activity exhibited a signature enriched for metabolic processes. Mild disease was distributed in two groups, exhibiting enhanced basic cellular functions, myelopoiesis, and autophagy. Bortezomib was predicted to reverse disturbances in the “neutrophilic” cluster, azathioprine and ixazomib in the “B-cell” cluster, and fostamatinib in the “metabolic” patient subgroup.ConclusionThe clinical spectrum of SLE encompasses distinct molecular endotypes, each defined by unique pathophysiologic aberrancies potentially reversible by distinct compounds.

Published
2022

87. Physician Global Assessment International Standardisation COnsensus in Systemic Lupus Erythematosus:the PISCOS study

Author

Piga, Matteo, Chessa, Elisabetta, Morand, Eric F., Ugarte-Gil, Manuel F., Tektonidou, Maria, van Vollenhoven, Ronald, Petri, Michelle, Arnaud, Laurent, Appenzeller, Simone, Aranow, Cynthia, Askanase, Anca, Avcin, Tadej, Bae, Sang Cheol, Bertsias, George, Bonfa, Eloisa, Cairoli, Ernesto, Cardiel, Mario H., Cervera, Ricard, Chasset, François, Chizzolini, Carlo, Clarke, Ann E., Conti, Fabrizio, Costedoat-Chalumeau, Nathalie, Czirják, László, Doria, Andrea, Dörner, Thomas, Espinosa, Gerard, Fischer-Betz, Rebecca, Garcìa, Mercedes, Gladman, Dafna D., González, Luis A., Gunnarsson, Iva, Hamijoyo, Laniyati, Hanly, John G., Hasni, Sarfaraz A., Houssiau, Frédéric A., Inanç, Murat, Inês, Luís S., Isenberg, David, Jacobsen, Soren, Jan Wu, Yeong Jian, Kaneko, Yuko, Katsumata, Yasuhiro, Lau, Chak S., Legge, Alexandra C., Lerang, Karoline, Limper, Maarten, Louthrenoo, Worawit, Luo, Shue Fen, Marinho, António, Piga, Matteo, Chessa, Elisabetta, Morand, Eric F., Ugarte-Gil, Manuel F., Tektonidou, Maria, van Vollenhoven, Ronald, Petri, Michelle, Arnaud, Laurent, Appenzeller, Simone, Aranow, Cynthia, Askanase, Anca, Avcin, Tadej, Bae, Sang Cheol, Bertsias, George, Bonfa, Eloisa, Cairoli, Ernesto, Cardiel, Mario H., Cervera, Ricard, Chasset, François, Chizzolini, Carlo, Clarke, Ann E., Conti, Fabrizio, Costedoat-Chalumeau, Nathalie, Czirják, László, Doria, Andrea, Dörner, Thomas, Espinosa, Gerard, Fischer-Betz, Rebecca, Garcìa, Mercedes, Gladman, Dafna D., González, Luis A., Gunnarsson, Iva, Hamijoyo, Laniyati, Hanly, John G., Hasni, Sarfaraz A., Houssiau, Frédéric A., Inanç, Murat, Inês, Luís S., Isenberg, David, Jacobsen, Soren, Jan Wu, Yeong Jian, Kaneko, Yuko, Katsumata, Yasuhiro, Lau, Chak S., Legge, Alexandra C., Lerang, Karoline, Limper, Maarten, Louthrenoo, Worawit, Luo, Shue Fen, and Marinho, António

Abstract

The Physician Global Assessment International Standardisation COnsensus in Systemic Lupus Erythematosus (PISCOS) study aimed to obtain an evidence-based and expert-based consensus standardisation of the Physician Global Assessment (PGA) scoring of disease activity in systemic lupus erythematosus (SLE). An international panel of 79 SLE experts participated in a three-round Delphi consensus process, in which 41 statements related to the PGA in SLE were rated, using a 0 (strongly disagree) to 10 (strongly agree) numerical rating scale. Statements with agreement of 75% or greater were selected and further validated by the expert panel. Consensus was reached on 27 statements, grouped in 14 recommendations, for the use of the PGA in SLE, design of the PGA scale, practical considerations for PGA scoring, and the relationship between PGA values and levels of disease activity. Among these recommendations, the expert panel agreed that the PGA should consist of a 0–3 visual analogue scale for measuring disease activity in patients with SLE in the preceding month. The PGA is intended to rate the overall disease activity, taking into account the severity of active manifestations and clinical laboratory results, but excluding organ damage, serology, and subjective findings unrelated to disease activity. The PGA scale ranges from “no disease activity” (0) to the “most severe disease activity” (3) and incorporates the values 1 and 2 as inner markers to categorise disease activity as mild (≥0·5 to 1), moderate (>1 and ≤2) and severe (>2 to 3). Only experienced physicians can rate the PGA, and it should be preferably scored by the same rater at each visit. The PISCOS results will allow for increased homogeneity and reliability of PGA ratings in routine clinical practice, definitions of remission and low disease activity, and future SLE trials.

Published
2022

88. A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)

Author

van Vollenhoven, Ronald, Voskuyl, Alexandre, Bertsias, George, Aranow, Cynthia, Aringer, Martin, Arnaud, Laurent, Askanase, Anca, Balážová, Petra, Bonfa, Eloisa, Bootsma, Hendrika, Boumpas, Dimitrios, Bruce, Ian, Cervera, Ricard, Clarke, Ann, Coney, Cindy, Costedoat-Chalumeau, Nathalie, Czirják, László, Derksen, Ronald, Doria, Andrea, Dörner, Thomas, Fischer-Betz, Rebecca, Fritsch-Stork, Ruth, Gordon, Caroline, Graninger, Winfried, Györi, Noémi, Houssiau, Frédéric, Isenberg, David, Jacobsen, Soren, Jayne, David, Kuhn, Annegret, Le Guern, Veronique, Lerstrøm, Kirsten, Levy, Roger, Machado-Ribeiro, Francinne, Mariette, Xavier, Missaykeh, Jamil, Morand, Eric, Mosca, Marta, Inanc, Murat, Navarra, Sandra, Neumann, Irmgard, Olesinska, Marzena, Petri, Michelle, Rahman, Anisur, Rekvig, Ole Petter, Rovensky, Jozef, Shoenfeld, Yehuda, Smolen, Josef, Tincani, Angela, Urowitz, Murray, van Leeuw, Bernadette, Vasconcelos, Carlos, Voss, Anne, Werth, Victoria P, Zakharova, Helena, Zoma, Asad, Schneider, Matthias, and Ward, Michael

Published
2017
Full Text
View/download PDF

92. Primary adrenal insufficiency due to bilateral adrenal hemorrhage-adrenal infarction in a patient with systemic lupus erythematosus and antiphospholipid syndrome

Author

Bouki, Katerina, primary, Venetsanaki, Vasiliki, additional, Chrysoulaki, Maria, additional, Pateromichelaki, Aikaterini, additional, Bertsias, George, additional, Daraki, Vasiliki, additional, Spanakis, Konstantinos, additional, Betsi, Grigoria, additional, Sbyrakis, Nikolaos, additional, Sfakiotaki, Maria, additional, Kontolaimaki, Kalliopi, additional, Syntzanaki, Eleni-Konstantina, additional, Vamvoukaki, Rodanthi, additional, Tsakalomatis, Panagiotis-Nikolaos, additional, Sidiropoulos, Prodromos, additional, and Xekouki, Paraskevi, additional

Published
2022
Full Text
View/download PDF

93. The relation of partners’ illness representations to the coping behaviors of patients with inflammatory rheumatic diseases through patients’ illness representation: A dyadic regulation process

Author

Dimitraki, Georgia, primary, Papastefanakis, Emmanouil, additional, Ktistaki, Georgia, additional, Fanouriakis, Antonis, additional, Adamichou, Christina, additional, Kougkas, Nikolaos, additional, Repa, Argyro, additional, Avgoustidis, Nestor, additional, Bertsias, George, additional, Sidiropoulos, Prodromos, additional, Vgontzas, Alexandros N., additional, Simos, Panagiotis G., additional, and Karademas, Evangelos C., additional

Published
2022
Full Text
View/download PDF

94. List of Contributors

Author

Agmon-Levin, Nancy, primary, Alarcón, Graciela S., additional, Amengual, Olga, additional, Ardoin, Stacy P., additional, Atkinson, John P., additional, Atsumi, Tatsuya, additional, Ayoub, Isabelle, additional, Bermas, Bonnie L., additional, Bernatsky, Sasha, additional, Bertsias, George, additional, Blanco, Patrick, additional, Bohgaki, Miyuki, additional, Bonsmann, Gisela, additional, Borghi, Maria Orietta, additional, Boumpas, Dimitrios T., additional, Bourn, Rebecka, additional, Buyon, Jill P., additional, Caricchio, Roberto, additional, Catalina, Michelle D., additional, Chan, Edward K.L., additional, Chang, Christopher, additional, Chartrand, Sandra, additional, Chighizola, Cecilia Beatrice, additional, Clarke, Ann E., additional, Crispín, José C., additional, Dai, Chao, additional, Damato, Erika M., additional, Deng, Yun, additional, Denniston, Alastair K.O., additional, Devlin, Amy, additional, Diamond, Betty, additional, Dooley, Mary Anne, additional, Drijvers, Jefte M., additional, du Bois, Roland M., additional, Du, Yong, additional, Ernandez, T., additional, Ferretti, Concetta, additional, Fischer, Aryeh, additional, Fisher, Samantha, additional, Frangou, Eleni A., additional, Fritzler, Marvin J., additional, Furie, Richard, additional, Fu, Shu Man, additional, Gaskin, Felicia, additional, Gilkeson, Gary S., additional, Gladman, Dafna, additional, Goldman, Rosalind Ramsey, additional, González-Naranjo, Luis A., additional, Gordon, Caroline, additional, Grammer, Amrie C., additional, Greidinger, Eric L., additional, Hagberg, Niklas, additional, Hanly, John G., additional, Hansen, James E., additional, Han, Shuhong, additional, Hasni, Sarfaraz A., additional, Hedrich, Christian M., additional, Horowitz, Diane, additional, Huang, Xin, additional, Izmirly, Peter M., additional, Jacquemin, Clément, additional, James, Judith, additional, Jarjour, Wael N., additional, Kaplan, Mariana J., additional, Khamashta, Munther, additional, Koike, Takao, additional, Kono, Dwight H., additional, Konya, Christine, additional, Kuhn, Annegret, additional, Kyttaris, Vasileios C., additional, La Cava, Antonio, additional, Lahita, Robert G., additional, Landmann, Aysche, additional, Lipsky, Peter E., additional, Lo, Mindy S., additional, Lu, Qianjin, additional, Mahieu, Mary, additional, Malkiel, Susan, additional, Manzi, Susan, additional, Marder, Galina, additional, Mayadas, T.N., additional, Means, Terry K., additional, Meroni, Pier Luigi, additional, Merrill, Joan T., additional, Mohan, Chandra, additional, Mok, Chi Chiu, additional, Moulton, Vaishali R., additional, Murray, Philip I., additional, Oates, Jim C., additional, Paz, Ziv, additional, Pendergraft, William F., additional, Perl, Andras, additional, Pillai, Shiv, additional, Pons-Estel, Guillermo J., additional, Qu, Bo, additional, Rahman, Anisur, additional, Ramsey-Goldman, Rosalind, additional, Reeves, Westley H., additional, Rodríguez-Rodríguez, Noé, additional, Rönnblom, Lars, additional, Rosetti, Florencia, additional, Rovin, Brad H., additional, Ryals, Matthew M., additional, Saggu, G., additional, Sammaritano, Lisa R., additional, Satoh, Minoru, additional, Sawalha, Amr H., additional, Saxena, Amit, additional, Sciascia, Savino, additional, Shaharir, Syahrul, additional, Shao, Chengqun, additional, Shen, Nan, additional, Shmerling, Robert, additional, Shoenfeld, Yehuda, additional, Shumyak, Stepan, additional, Slight-Webb, Samantha, additional, Stillman, Isaac Ely, additional, Stojan, George, additional, Sung, Sun-Sang J., additional, Theofilopoulos, Argyrios N., additional, Thomas Jr., Donald E., additional, Tissera, Hiromi, additional, Touma, Zahi, additional, Tsao, Betty P., additional, Ugarte-Gil, Manuel F., additional, Urowitz, Murray B., additional, Volpe, Bruce T., additional, Wang, Hongyang, additional, Wener, Mark H., additional, Wu, Haijing, additional, Xu, Yuan, additional, Yang, Lijun, additional, Yu, C. Yung, additional, and Zhuang, Haoyang, additional

Published
2016
Full Text
View/download PDF

96. sj-pdf-1-lup-10.1177_09612033221074580 ��� Supplemental Material for The association between lupus serology and disease outcomes: A systematic literature review to inform the treat-to-target approach in systemic lupus erythematosus

Author

Kostopoulou, Myrto, Ugarte-Gil, Manuel F, Pons-Estel, Bernardo, van Vollenhoven, Ronald F, and Bertsias, George

Subjects
immune system diseases, 111702 Aged Health Care, FOS: Health sciences, skin and connective tissue diseases
Abstract

Supplemental Material, sj-pdf-1-lup-10.1177_09612033221074580 for The association between lupus serology and disease outcomes: A systematic literature review to inform the treat-to-target approach in systemic lupus erythematosus by Myrto Kostopoulou, Manuel F Ugarte-Gil, Bernardo Pons-Estel, Ronald F van Vollenhoven and George Bertsias in Lupus

Published
2022
Full Text
View/download PDF

97. Additional file 5 of Baseline IgG-Fc N-glycosylation profile is associated with long-term outcome in a cohort of early inflammatory arthritis patients

Author

Sénard, Thomas, Flouri, Irini, Vučković, Frano, Papadaki, Garyfalia, Goutakoli, Panagiota, Banos, Aggelos, Pučić-Baković, Maja, Pezer, Marija, Bertsias, George, Lauc, Gordan, and Sidiropoulos, Prodromos

Abstract

Additional file 5: Supplementary Table 3. Association of the relative abundances of IgG N-glycoforms of the two diagnosis groups and the different clinical outcomes (“favorable outcome” and “adverse outcomes 1” and “2”). Standard errors, p-values and p-values adjusted for multiple testing were calculated based on the general linear model with age, sex and duration of symptoms included as additional covariates. Statistically significant associations are described by an adjusted p-value < 0.05.

Published
2022
Full Text
View/download PDF

98. Additional file 1 of Accrual of organ damage in Behçet’s syndrome: trajectory, associated factors, and impact on patients’ quality of life over a 2-year prospective follow-up study

Author

Floris, Alberto, Piga, Matteo, Laconi, Riccardo, Espinosa, Gerard, Lopalco, Giuseppe, Serpa Pinto, Luisa, Kougkas, Nikolaos, Sota, Jurgen, Lo Monaco, Andrea, Govoni, Marcello, Cantarini, Luca, Bertsias, George, Correia, João, Iannone, Florenzo, Cervera, Ricard, Vasconcelos, Carlos, Mathieu, Alessandro, and Cauli, Alberto

Abstract

Additional file 1: Supplementary Figure 1. Flow chart representing the patients’ recruiting process from the BODI validation cohort.

Published
2022
Full Text
View/download PDF

99. Additional file 3 of Baseline IgG-Fc N-glycosylation profile is associated with long-term outcome in a cohort of early inflammatory arthritis patients

Author

Sénard, Thomas, Flouri, Irini, Vučković, Frano, Papadaki, Garyfalia, Goutakoli, Panagiota, Banos, Aggelos, Pučić-Baković, Maja, Pezer, Marija, Bertsias, George, Lauc, Gordan, and Sidiropoulos, Prodromos

Abstract

Additional file 3: Supplementary Table 1. Average relative abundances, standard deviations (SD), coefficients of variation (CV) and median CVs of IgG N-glycoforms, from the 7 serum standards, quantified with the LaCyTools software. Relative abundances were calculated following normalization of total intensity as described in the Methods section.

Published
2022
Full Text
View/download PDF

100. IL-6 Signaling Attenuates TNF-α Production by Plasmacytoid Dendritic Cells in Rheumatoid Arthritis

Author

Papadaki, Garyfalia, Goutakoli, Panagiota, Tiniakou, Ioanna, Grün, Joachim R, Grützkau, Andreas, Pavlopoulos, Georgios A, Iliopoulos, Ioannis, Bertsias, George, Boumpas, Dimitrios, Ospelt, Caroline, Reizis, Boris, Sidiropoulos, Prodromos, Verginis, Panayotis, and University of Zurich

Subjects
Arthritis, Rheumatoid, Interleukin-6, Tumor Necrosis Factor-alpha, Immunology, 10051 Rheumatology Clinic and Institute of Physical Medicine, Immunology and Allergy, Humans, Tumor Necrosis Factor Inhibitors, 610 Medicine & health, Dendritic Cells, Signal Transduction
Abstract

Rheumatoid arthritis (RA) is characterized by autoimmune joint destruction with debilitating consequences. Despite treatment advancements with biologic therapies, a significant proportion of RA patients show an inadequate clinical response, and restoration of immune self-tolerance represents an unmet therapeutic need. We have previously described a tolerogenic phenotype of plasmacytoid dendritic cells (pDCs) in RA patients responding to anti–TNF-α agents. However, the molecular mechanisms involved in tolerogenic reprogramming of pDCs in RA remain elusive. In this study, guided by transcriptomic analysis of CD303+CD123+ pDCs from RA patients in remission, we revealed enhanced expression of IL-6R and its downstream signaling compared with healthy pDCs. Functional assessment demonstrated that IL-6R engagement resulted in marked reduction of TNF-α secretion by pDCs whereas intracellular TNF-α was significantly increased. Accordingly, pharmacologic inhibition of IL-6R signaling restored TNF-α secretion levels by pDCs. Mechanistic analysis demonstrated impaired activity and decreased lysosomal degradation of ADAM17 (a disintegrin and metalloproteinase 17) sheddase in pDCs, which is essential for TNF-α cleavage. Importantly, reduction of TNF-α secretion by IL-6–treated pDCs attenuated the inflammatory potential of RA patient–derived synovial fibroblasts. Collectively, these findings position pDCs as an important source of TNF-α in RA pathogenesis and unravel an anti-inflammatory mechanism of IL-6 by limiting the pDC-derived TNF-α secretion.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results